Cookie Settings
 
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Welcome to Nexplace: the home of
NEXPLANON® (etonogestrel 68 mg implant)

NEXPLANON® is indicated for contraception. Safety and efficacy have been established in women between 18 and 40 years of age.1

Login/Register

To view the content on this page

How might NEXPLANON® benefit your practice and the NHS?

REDUCE COSTS ASSOCIATED WITH UNINTENDED PREGNANCIES:

45% of pregnancies in England are unplanned or are associated with feelings of ambivalence.2*

£817 million per year is the estimated cost to the NHS of unintended pregnancies.3†

Comparisons of the cost-effectiveness between different contraceptive methods have shown:4‡

  • All currently available LARC methods are more cost-effective over the long term than the combined pill

LARCs CAN GENERATE INCOME FOR YOUR PRACTICE5

LARCs such as intrauterine devices and implants can be added to the GP contract through the Local Enhanced Services system.5

REDUCE PRESSURE
ON MATERNITY SERVICES

Since 2015, 1 in 3 local authorities (LAs) have reduced (or plan to reduce) the number of sites that deliver contraceptive services.

Increasing the uptake of LARCs can reduce the number of unintended pregnancies,4 which may reduce the number of terminations and maternity services needed.

Are you confident discussing NEXPLANON®
with women seeking contraception?

View our tips to support your
consultations, including:

  • what questions to ask
  • information on common side effects

LARC: long-acting reversible contraceptive

*Correct as of June 2018.2

†Data from a cross party inquiry into unplanned pregnancy. This figure was estimated from data submitted by Bayer Healthcare.3

‡Studies comparing cost-effectiveness of contraceptive methods measure the cost savings that result from averted pregnancies. The efficacy of each method in averting pregnancies is usually calculated from their individual failure rates.4

§53 out of 152 LAs over the period 2015/16 to 2017/18.6

References

  1. NEXPLANON® Summary of Product Characteristics
  2. gov.uk. Guidance. Health matters: reproductive health and pregnancy planning, June 2018. Available at: gov.uk. Accessed July 2021
  3. 2020health. The morning after: a cross party inquiry into unplanned pregnancy, February 2013. Available at: https://2020health.org. Accessed July 2021
  4. Public Health England. Contraception: economic analysis estimation of the return on investment (ROI) for publicly funded contraception in England, June 2018. Available at: https://assets.publishing.service.gov.uk. Accessed July 2021
  5. Department of Health. Commissioning sexual health services and interventions, March 2013. Available at: https://assets.publishing.service.gov.uk. Accessed July 2021
  6. Advisory Group on Contraception. Cuts, closures and contraception, November 2017. Available at: http://theagc.org.uk. Accessed July 2021

GB-XPL-115002 | Date of preparation: July 2021